We are live on ! Find out more
EBS icon

Emergent Biosolutions

208 hedge funds and large institutions have $1.17B invested in Emergent Biosolutions in 2016 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 76 increasing their positions, 67 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more call options, than puts

Call options by funds: $1.32M | Put options by funds: $804K

32% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 28

13% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 67

2% more funds holding

Funds holding: 203208 (+5)

2% more capital invested

Capital invested by funds: $1.15B → $1.17B (+$24.6M)

2.25% less ownership

Funds ownership: 90.5%88.25% (-2.2%)

Holders
208
Holders Change
+5
Holders Change %
+2.46%
% of All Funds
5.2%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
37
Increased
76
Reduced
67
Closed
28
Calls
$1.32M
Puts
$804K
Net Calls
+$513K
Net Calls Change
-$2.49M
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
51
Millennium Management
New York
$4.8M +$4.38M +146,117 New
TRSOTSOK
52
Teachers Retirement System of the State of Kentucky
Kentucky
$4.79M +$172K +5,740 +4%
CRC
53
Curi RMB Capital
Illinois
$4.47M +$47.6K +1,587 +1%
Two Sigma Advisers
54
Two Sigma Advisers
New York
$4.43M -$756K -25,200 -16%
New York State Common Retirement Fund
55
New York State Common Retirement Fund
New York
$4.24M +$580K +19,330 +18%
Prudential Financial
56
Prudential Financial
New Jersey
$4.08M -$3.96M -132,173 -52%
Citigroup
57
Citigroup
New York
$3.8M +$2.68M +89,298 +339%
QI
58
QS Investors
New York
$3.67M -$748K -24,951 -18%
Jacobs Levy Equity Management
59
Jacobs Levy Equity Management
New Jersey
$3.47M +$1.13M +37,540 +55%
Wells Fargo
60
Wells Fargo
California
$3.43M -$4.4M -146,907 -58%
SCP
61
Seizert Capital Partners
Michigan
$3.36M +$12.3K +411 +0.4%
Wellington Management Group
62
Wellington Management Group
Massachusetts
$3.29M -$2.1M -69,938 -41%
CIM
63
Calvert Investment Management
Maryland
$3.21M -$418K -13,930 -12%
FP
64
Foundry Partners
Minnesota
$3.19M +$2.91M +96,982 New
GCP
65
GSA Capital Partners
United Kingdom
$3.13M -$847K -28,236 -23%
TCIM
66
TIAA CREF Investment Management
New York
$3.1M -$160K -5,336 -5%
Bank of Montreal
67
Bank of Montreal
Ontario, Canada
$3.02M +$1.71M +57,197 +103%
AL
68
AJO LP
Pennsylvania
$2.85M -$1.7M -56,559 -39%
BG
69
BlackRock Group
United Kingdom
$2.8M +$513K +17,107 +25%
OAM
70
Oxford Asset Management
United Kingdom
$2.72M -$345K -11,520 -12%
CCMH
71
Cornerstone Capital Management Holdings
New York
$2.59M -$1.37M -45,591 -37%
Allianz Asset Management
72
Allianz Asset Management
Germany
$2.52M -$2.26M -75,254 -49%
Citadel Advisors
73
Citadel Advisors
Florida
$2.49M +$344K +11,473 +18%
California State Teachers Retirement System (CalSTRS)
74
California State Teachers Retirement System (CalSTRS)
California
$2.2M -$54K -1,800 -3%
CAM
75
ClariVest Asset Management
California
$2.09M -$1.86K -62 -0.1%

EBS Hedge Fund Activity: Q4 2016 in Review

208 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2016, worth a combined $1.17B — up 2.1% from $1.15B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new EBS positions and 28 closed out — a net gain of 9 holders — while 76 added to existing stakes and 67 trimmed.

The largest buyer was Royal Bank of Canada, adding an estimated $12M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $23.3M sold.

  • 208 institutional investors held Emergent Biosolutions (EBS) as of Q4 2016, up from 203 in Q3 2016.
  • Funds reported $1.17B of Emergent Biosolutions stock for Q4 2016, up 2.1% quarter-over-quarter.
  • 37 funds opened new Emergent Biosolutions positions in Q4 2016 and 28 closed out, a net change of +9 holders.
  • The largest Emergent Biosolutions buyer in Q4 2016 was Royal Bank of Canada, an estimated $12M added.
  • The largest Emergent Biosolutions seller in Q4 2016 was Arrowstreet Capital, an estimated $23.3M sold.

Based on aggregated 13F filings for Q4 2016.